Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

HC Wainwright backs Achieve Life Sciences with a Buy rating as cytisinicline nears potential 2026 FDA approval, targeting a large smoking cessation market.

Latest Ratings for ACHV

DateFirmActionFromTo Oct 2021Alliance Global PartnersInitiates Coverage OnBuy Jun 2021OppenheimerInitiates Coverage OnOutperform Sep 2020Lake StreetInitiates Coverage OnBuy

View More Analyst Ratings for ACHV

View the Latest Analyst Ratings

read more